|
|
|
|
|
by Malician
4639 days ago
|
|
I believe he's suggesting that the doctor could have legally covered up the results of the first trial (by simply not releasing them,) then run a second trial on only the most beneficial population, releasing those results without mentioning the first trial. At that point, his product would look great, hiding its failures. This way, while he misinterpreted the P value in an illegal and fraudulent way, he did release all relevant information - ironically, better for the informed reader than if he had rerun the trial legally. |
|
It would be absolutely fine to run a new trial on the supposedly most beneficial population (those with mild/moderate lung damage; lets call them 'the subpopulation').
If that second trial succeeded, then it would be strong evidence that the drug was beneficial for the subpopulation.
There would be no need to hide the results of the first trial, as the first trial did not provide evidence that the drug didn't work on the subpopulation.
If you read the article to the end, they did in fact do such a trial on the subpopulation. And they got evidence it wasn't working on the subpopulation - which is how science goes.
The problem was that the first trial wasn't set up to examine the subpopulation, but they reported results as if it was. You can't do that with standard NHST, as it invalidates the assumptions of the statistical framework being used.
But you can absolutely decide to run a whole new test on a new sub population, based on hints you get from the first results.
And, while it'd in general be better if all test results (positive AND negative) were published, that is not relevant to this situation - the first trial said nothing bad about the effects on the subpopulation, so there'd be nothing to gain from hiding it, if you just wanted to claim it worked on the subpopulation.
Its not like a situation where they got evidence that the subpopulation would not benefit in the drug in the first test, and then decided to do another test, planning to only report the second.